Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Pombiliti | cipaglucosidase alfa-atga | Amicus Therapeutics | N-761204 RX | 2023-09-28 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
pombiliti | Biologic Licensing Application | 2024-07-29 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
glycogen storage disease type ii | Orphanet_365 | D006009 | E74.02 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glycogen storage disease type ii | D006009 | Orphanet_365 | E74.02 | 10 | 8 | 5 | 7 | 10 | 35 |
Glycogen storage disease | D006008 | — | E74.0 | — | 1 | 2 | 6 | 2 | 11 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 2 | 5 | 1 | 8 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 2 | 5 | — | 7 |
Glycogen storage disease type iii | D006010 | Orphanet_366 | E74.03 | — | — | 1 | 3 | — | 4 |
Liver diseases | D008107 | HP_0002910 | K70-K77 | — | — | — | 1 | — | 1 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | 1 | — | 1 |
Fatty liver | D005234 | EFO_0003934 | — | — | — | — | 1 | — | 1 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Disease | D004194 | EFO_0000408 | R69 | — | — | 1 | — | — | 1 |
Deficiency diseases | D003677 | EFO_1001067 | E63 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypotension | D007022 | EFO_0005251 | I95 | — | 1 | — | — | — | 1 |
Syncope | D013575 | HP_0012668 | G90.01 | — | 1 | — | — | — | 1 |
Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 1 | — | — | — | 1 |
Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | — | — | — | 1 |
Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ataxia | D001259 | — | R27.0 | — | — | — | — | 2 | 2 |
Cerebellar ataxia | D002524 | HP_0001251 | — | — | — | — | — | 2 | 2 |
Overweight | D050177 | — | E66.3 | — | — | — | — | 1 | 1 |
Deglutition disorders | D003680 | HP_0002015 | R13.1 | — | — | — | — | 1 | 1 |
Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 1 | 1 |
Lysosomal storage diseases | D016464 | — | — | — | — | — | — | 1 | 1 |
Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 1 | 1 |
Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | — | — | — | — | 1 | 1 |
Muscular dystrophies | D009136 | HP_0003560 | G71.0 | — | — | — | — | 1 | 1 |
Myalgia | D063806 | HP_0003326 | M79.1 | — | — | — | — | 1 | 1 |
Drug common name | Cipaglucosidase alfa |
INN | cipaglucosidase alfa |
Description | Cipaglucosidase alfa, sold under the brand name Pombiliti, and used in combination with miglustat, is a medication used for the treatment of glycogen storage disease type II (Pompe disease). Cipaglucosidase alfa is a recombinant human acid α-glucosidase enzyme replacement therapy that provides an exogenous source of acid α-glucosidase.
|
Classification | Enzyme |
Drug class | enzymes |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4594329 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16708 |
UNII ID | 4SED7F4BSG (ChemIDplus, GSRS) |